SB656933

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Cystic Fibrosis

Phase 1

SD Cystic Fibrosis Study

CompletedNCT00605761

GlaxoSmithKlineCystic Fibrosis

Start: 2008-02-29End: 2008-12-31Updated: 2012-03-19

Phase 2

28 Day Repeat Dose in Cystic Fibrosis Patients

CompletedNCT00903201

GlaxoSmithKlineCystic Fibrosis

Start: 2009-09-28End: 2010-12-29Updated: 2017-11-17

Related Papers

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

2012-09-1794 citations